Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast

   Sartorius Stedim Biotech SA / Key word(s): Miscellaneous
   Sartorius Stedim Biotech Capital Markets: Links to presentation
   and webcast
   17-May-2024 / 19:32 CET/CEST
     ____________________________________________________________

   
    Aubagne, France | May 17, 2024

   Sartorius Stedim Biotech Capital Markets: Links to presentation
   and webcast

   Sartorius Stedim Biotech held its Capital Markets Day (CMD)
   yesterday presenting its business strategy and goals. The company
   explained and confirmed its forecast for 2024 and the medium-term
   ambition up to 2028. In order to ensure broad access to the CMD
   presentation, which has been published on the company's website
   since the start of the CMD, we hereby refer to the corresponding
   link. We are also providing the link to the webcast.

Capital Markets Day Presentation

Webcast



Financial calendar

   July 19, 2024   Publication of the first-half figures (January to
   June 2024)

   October 17, 2024 Publication of the nine-month figures (January
   to September 2024)

A profile of Sartorius Stedim Biotech

   Sartorius Stedim Biotech is a leading international partner of
   the biopharmaceutical industry. As a provider of innovative
   solutions, the company based in Aubagne, France, helps its
   customers to manufacture biotech medications, such as cell and
   gene therapies, safely, rapidly, and economically. The shares of
   Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
   The company has a strong global reach with manufacturing and R&D
   sites as well as sales entities in Europe, North America, and
   Asia. Sartorius Stedim Biotech regularly expands its portfolio
   through acquisitions of complementary technologies. In 2023, the
   company generated sales revenue of around 2.8 billion euros. By
   the end of 2023, more than 10,600 employees were working for
   customers around the globe.

   Visit our newsroom and follow Sartorius Stedim Biotech on
   LinkedIn.

Contact

Petra Kirchhoff

Head of Corporate Communications & Investor Relations

+49 (0)551 308 1686

petra.kirchhoff@sartorius.com

____________________________________________________________

   Dissemination of a Financial Wire News, transmitted by EQS Group.
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   Language:    English
   Issuer:      Sartorius Stedim Biotech SA
                Avenue de Jouques
                13781 Aubagne
                France
   Phone:       +33 44 284 5600
   E-mail:      sartorius.presse@sartorius.com
   Internet:    www.sartorius-stedim.com
   ISIN:        FR0013154002
   EQS News ID: 1906303

   End of Announcement - EQS News Service
     ____________________________________________________________

1906303 17-May-2024 CET/CEST